Advertisement

U.S. Markets closed

S&P Futures
5,889.00
-3.50(-0.06%)
Dow Futures
43,049.00
-120.00(-0.28%)
Nasdaq Futures
20,523.50
-18.50(-0.09%)
Russell 2000 Futures
2,244.70
-1.50(-0.07%)
Crude Oil
72.24
+0.15(+0.21%)
Gold
2,753.50
-6.30(-0.23%)

SciSparc Ltd. (SPRC)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD

0.2507

-0.0393

(-13.55%)

At close: 04:00PM EDT

0.2410

-0.01

(-3.87%)

After hours:

07:47PM EDT

Trade prices are not sourced from all markets

All

Clinical Trials Arena
SciSparc receives FDA approval for trial for Tourette syndrome therapy
The trial's primary goal is to assess the efficacy, safety and tolerability of daily oral doses of SCI-110 in adults aged 18 to 65 years.
GlobeNewswire
SciSparc Secures FDA Green Light to US Launch of its Pivotal Phase IIb Clinical Trial for Breakthrough Tourette Syndrome Treatment
FDA confirms that SciSparc’s study may proceed only a month after application submission TEL AVIV, Israel, Sept. 30, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced that the U.S. Food and Drug Administration (“FDA”) has confirmed that its investigational new drug (“IND”) application for its first